Evidence map›Paper›PMID 37312878›Full record

ArticlePeerJ2023

Triptoquinone A and B exercise a therapeutic effect in systemic lupus erythematosus by regulating NLRC3.

Qinyao Xu, Xiangzhi Zhang, Shangqing Ge, Chang Xu, Yuanfan Lv, Zongwen Shuai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Qinyao Xu *Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Xiangzhi Zhang *Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Shangqing GeDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Chang XuDepartment of Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yuanfan LvDepartment of Internal Medicine, School Hospital of Anhui Medical University, Hefei, China.
Zongwen ShuaiDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Anhui Medical University · CNFirst Affiliated Hospital of Anhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The autoimmune disorder systemic lupus erythematosus (SLE) is multifaceted, with limited therapeutic alternatives and detrimental side effects, particularly on bones and joints. This research endeavors to examine the curative potential and underlying mechanisms of in addressing SLE-associated bone and joint complications. Triptoquinone A and triptoquinone B, constituents of

Indexed as

Autoimmune DiseasesDiterpenesLupus Erythematosus, SystemicHumansIntercellular Signaling Peptides and ProteinsProspective StudiesDiterpenesIntercellular Signaling Peptides and ProteinsNLRC3 protein, humantriptoquinone AApoptosisChondrocytesInflammationNLRC3Oxidative stressSystemic lupus erythematosus (SLE)Triptoquinone

Identifiers

PMID37312878
PMCPMC10259444
OpenAlexW4380087607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.